Methylome-wide association studies and epigenetic biomarker development for 133 mass spectrometry-assessed circulating proteins in 14,671 Generation Scotland participants

Janet Robertson, Jakub Bajzík, Spyros I. Vernardis, Aleksandra D. Chybowska, Daniel L. McCartney, Arturas Grauslys, Jure Mur, Hannah M. Smith, Archie Campbell, Camilla Drake, Hannah Grant, Jamie Pearce, Tom C. Russ, Poppy Adkin, Matthew White, Charles Brigden, Christoph B. Messner, David J. Porteous, Caroline Hayward, Simon R. Cox, Aleksej Zelezniak, Markus Ralser, Matthew R. Robinson, Riccardo E. MarioniGenome 2025 · DOI

Abstract

DNA methylation (DNAm) patterns, or epigenetic scores (EpiScores), can serve as stable biomarkers for complex traits, potentially offering a more consistent assessment of chronic exposures than single-point protein measurements. This study presents the first large-scale epigenetic analysis of the high-abundance serum proteome, measured via mass spectrometry in 14,671 participants from the Generation Scotland cohort. We identified thousands of significant CpG-protein associations and developed 112 validated protein EpiScores. Notably, sixteen of these EpiScores were significantly associated with incident cardiovascular disease (CVD), outperforming directly measured proteins. These findings suggest that protein EpiScores are powerful clinical biomarkers for disease risk prediction.

Introduction

Circulating proteins are vital indicators of physiological state, yet most proteomic research focuses on low-abundance signaling molecules. The "high-abundance" proteome—comprising 99% of total protein mass, including albumin and transport proteins—remains understudied despite its roles in immunity and coagulation. Furthermore, protein levels can be transiently affected by factors like diet or acute infection. In contrast, DNA methylation (DNAm) is relatively stable and may capture cumulative biological history. This research explores whether DNAm patterns can act as reliable proxies (EpiScores) for high-abundance proteins and improve the prediction of chronic conditions like cardiovascular disease (CVD).

Methods and Study Design

The study utilized data from 14,671 participants in the Generation Scotland cohort. Researchers employed two primary statistical frameworks to map the relationship between CpG sites and 133 proteins:

  1. OSCA (Marginal Linear Regression): Tested individual CpG sites against proteins, adjusting for age, sex, batch, and other covariates.
  2. GMRMomi (Bayesian Penalized Regression): A joint modeling approach used to fine-map influential CpG sites and generate parsimonious models for EpiScore creation.
Overview of the study workflow, including marginal regression analysis and Bayesian penalized regression for EpiScore generation.

The cohort was split into a training set (N=6,816) and a holdout test set (N=3,463) to validate the EpiScores. Finally, Cox proportional hazards models assessed the predictive power of these scores for incident CVD over a 17-year follow-up.

Key Results

The marginal models identified 15,855 significant CpG–protein associations across 125 proteins. The more stringent Bayesian approach narrowed this to 697 high-confidence associations. Validation in the test set confirmed that 112 of the 133 protein EpiScores significantly correlated with their measured protein counterparts.

Pleiotropy and Regulatory Insights

The study highlighted significant pleiotropy, where specific CpG sites were associated with multiple proteins. For example, one site (cg06072257) was linked to 22 different proteins, suggesting a broad regulatory role in metabolic processes.

Distribution of CpG counts across protein association counts, highlighting the pleiotropic nature of certain epigenetic sites.

Clinical Predictive Power

The most significant finding was the superior performance of EpiScores in predicting incident CVD. While only one directly measured protein showed a significant association with CVD, sixteen protein EpiScores were significant predictors. For instance, the EpiScore for Gelsolin (GSN) showed a clear protective association (Hazard Ratio: 0.61), which was not as evident in the raw protein measurements.

Discussion

The "chronic advantage" of EpiScores likely stems from DNAm's ability to reflect long-term environmental and biological impacts, whereas protein measures provide only a temporal snapshot. The discovery of strong associations between blood-based DNAm and liver-synthesized proteins suggests that white blood cell methylation captures systemic states like inflammation that influence overall proteomic output.

While limited by a primarily European ancestry cohort and a cross-sectional design for the initial mapping, this work demonstrates that the high-abundance proteome is a rich source of clinical biomarkers. Future diagnostic and prognostic tools may benefit from integrating both direct protein measurements and their corresponding epigenetic proxies to better monitor and predict disease risk.

Summary updated

Abstract

DNA methylation (DNAm) can regulate gene expression, and its genome-wide patterns (epigenetic scores or EpiScores) can act as biomarkers for complex traits. The relative stability of methylation profiles may enable better assessment of chronic exposures compared to single time-point protein measures. We present the first large-scale epigenetic study of the highly-abundant serum proteome measured via ultra-high throughput mass spectrometry in 14,671 samples from the Generation Scotland cohort. We further demonstrate the first large-scale comparison of protein EpiScores and their respective proteins as predictors of incident cardiovascular disease. Marginal epigenome-wide association models, adjusting for age, sex, measurement batch, estimated white cell proportions, BMI, smoking and methylation principal components, reveal 15,855 significant CpG – protein associations across 125 of 133 proteins PBonferroni < 2.71 × 10-10. Bayesian epigenome-wide association studies of the same 133 proteins reveal 697 CpG-Protein associations (posterior inclusion probability > 0.95). 112 protein EpiScores correlate significantly with their respective protein in a holdout test-set. Of these, sixteen associate significantly with incident all-cause cardiovascular disease (Nevents=191) compared to one measured protein. We highlight a complex interplay between the blood-based methylome and proteome. Importantly, we show that protein EpiScores correlate with measured proteins and demonstrate that the, as-yet understudied, high-abundance proteome may yield clinically relevant biomarkers. The protein EpiScores demonstrate more significant associations with cardiovascular disease than directly measured proteins, suggesting their potential as clinical biomarkers for monitoring or predicting disease risk. We suggest that biomarker development could be enhanced by the consideration of protein EpiScores alongside measured proteins.
BibTeX
@inproceedings{robertson2025methylome,
  author = {Janet Robertson and Jakub Bajzík and Spyros I. Vernardis and Aleksandra D. Chybowska and Daniel L. McCartney and Arturas Grauslys and Jure Mur and Hannah M. Smith and Archie Campbell and Camilla Drake and Hannah Grant and Jamie Pearce and Tom C. Russ and Poppy Adkin and Matthew White and Charles Brigden and Christoph B. Messner and David J. Porteous and Caroline Hayward and Simon R. Cox and Aleksej Zelezniak and Markus Ralser and Matthew R. Robinson and Riccardo E. Marioni},
  title = {{Methylome-wide association studies and epigenetic biomarker development for 133 mass spectrometry-assessed circulating proteins in 14,671 Generation Scotland participants}},
  booktitle = {Genome},
  year = {2025},
  doi = {10.1186/s13059-025-03892-0},
}
Figure